Log in

NASDAQ:SLGLSol Gel Technologies Stock Price, Forecast & News

+0.07 (+0.92 %)
(As of 06/1/2020 04:00 PM ET)
Today's Range
Now: $7.72
50-Day Range
MA: $8.11
52-Week Range
Now: $7.72
Volume12,200 shs
Average Volume60,333 shs
Market Capitalization$157.41 million
P/E RatioN/A
Dividend YieldN/A
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.
Read More
Sol Gel Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SLGL



Sales & Book Value

Annual Sales$22.90 million
Book Value$2.57 per share


Net Income$-24,610,000.00
Net Margins-129.88%


Market Cap$157.41 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive SLGL News and Ratings via Email

Sign-up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.

Sol Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions

How has Sol Gel Technologies' stock been impacted by COVID-19 (Coronavirus)?

Sol Gel Technologies' stock was trading at $8.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SLGL shares have decreased by 6.4% and is now trading at $7.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sol Gel Technologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sol Gel Technologies.

When is Sol Gel Technologies' next earnings date?

Sol Gel Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Sol Gel Technologies.

How were Sol Gel Technologies' earnings last quarter?

Sol Gel Technologies Ltd (NASDAQ:SLGL) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.33) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.05. The company earned $3.47 million during the quarter, compared to the consensus estimate of $3.37 million. Sol Gel Technologies had a negative net margin of 129.88% and a negative return on equity of 44.64%. View Sol Gel Technologies' earnings history.

What price target have analysts set for SLGL?

4 brokers have issued 12-month price objectives for Sol Gel Technologies' stock. Their forecasts range from $21.00 to $33.00. On average, they expect Sol Gel Technologies' share price to reach $25.25 in the next twelve months. This suggests a possible upside of 227.1% from the stock's current price. View analysts' price targets for Sol Gel Technologies.

Has Sol Gel Technologies been receiving favorable news coverage?

Media coverage about SLGL stock has trended very positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sol Gel Technologies earned a news sentiment score of 3.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutSol Gel Technologies.

Are investors shorting Sol Gel Technologies?

Sol Gel Technologies saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 53,400 shares, a drop of 18.8% from the April 30th total of 65,800 shares. Based on an average trading volume of 65,100 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.7% of the company's stock are sold short. View Sol Gel Technologies' Current Options Chain.

Who are some of Sol Gel Technologies' key competitors?

What other stocks do shareholders of Sol Gel Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol Gel Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Tesla (TSLA), Advanced Micro Devices (AMD), eHealth (EHTH), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA), Micron Technology (MU) and NeoPhotonics (NPTN).

Who are Sol Gel Technologies' key executives?

Sol Gel Technologies' management team includes the following people:
  • Dr. Alon Seri-Levy, Co-Founder, CEO & Director (Age 58)
  • Mr. Gilad Mamlok, Chief Financial Officer (Age 51)
  • Mr. Itzik Yosef, VP of Operations (Age 43)
  • Dr. Ofer Toledano, VP of R&D (Age 54)
  • Dr. Ofra Levy-Hacham Ph.D., VP of Clinical & Regulatory Affairs (Age 53)

When did Sol Gel Technologies IPO?

(SLGL) raised $60 million in an initial public offering (IPO) on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

What is Sol Gel Technologies' stock symbol?

Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

Who are Sol Gel Technologies' major shareholders?

Sol Gel Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Phoenix Holdings Ltd. (13.25%), Ion Asset Management Ltd. (1.24%), Invesco Ltd. (0.39%), Raymond James Financial Services Advisors Inc. (0.22%), Raymond James & Associates (0.20%) and Morgan Stanley (0.09%).

Which institutional investors are buying Sol Gel Technologies stock?

SLGL stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Ion Asset Management Ltd., Invesco Ltd., Two Sigma Investments LP, Morgan Stanley, Raymond James Financial Services Advisors Inc., Raymond James & Associates, and Steward Partners Investment Advisory LLC.

How do I buy shares of Sol Gel Technologies?

Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sol Gel Technologies' stock price today?

One share of SLGL stock can currently be purchased for approximately $7.72.

How big of a company is Sol Gel Technologies?

Sol Gel Technologies has a market capitalization of $157.41 million and generates $22.90 million in revenue each year. The company earns $-24,610,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

What is Sol Gel Technologies' official website?

The official website for Sol Gel Technologies is www.sol-gel.com.

How can I contact Sol Gel Technologies?

Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The company can be reached via phone at 972-8931-3429 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.